Proveca, a Manchester, UK-based specialist pharmaceutical company developing medicines for children, raised £4m in funding.
The round was led by Catapult Ventures, manager of the Greater Manchester and Cheshire Life Sciences Fund, with growth debt financing provided by Kreos Capital.
The company intends to use the funds for the commercial roll-out of Sialanar.
Led by Dr Simon Bryson and Dr Helen Shaw, Proveca is a pharmaceutical company specializing in identifying, developing and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market.
The company’s Sialanar is a treatment for chronic pathological drooling in children.